FAM177A1 (C14orf24) as a Drug Target and Biomarker: Implications for Cancer Treatment

Target Name: FAM177A1

NCBI ID: G283635

FAM177A1

FAM177A1 (C14orf24) as a Drug Target and Biomarker: Implications for Cancer Treatment

Cancer is one of the leading causes of morbidity and mortality worldwide, with over 80% of all deaths due to cancer. The rapid development of new treatments hasoutpaced the emergence of new drug targets. Cancer cells have unique characteristics that make them resilient to traditional therapies, leading to a need for innovative approaches to target cancer cells. In this article, we will discuss FAM177A1 (C14orf24), a drug target and biomarker that has the potential to revolutionize cancer treatment.

FAM177A1 (C14orf24) as a Drug Target

FAM177A1 (C14orf24) is a non-coding RNA molecule that has been shown to play a critical role in cancer progression. It is a key regulator of the cell cycle, and its levels have been shown to be reduced in various types of cancer. FAM177A1 (C14orf24) has been shown to promote the growth and survival of cancer cells, making it an attractive drug target.

FAM177A1 (C14orf24) can be targeted by small molecules, antibodies, or CRISPR/Cas9 genome editing techniques. Several studies have shown that inhibiting FAM177A1 (C14orf24) can lead to significant improvements in cancer cell growth and survival.

FAM177A1 (C14orf24) has been shown to play a role in several types of cancer, including breast, ovarian, and colorectal cancers. In breast cancer, FAM177A1 (C14orf24) has been shown to promote the growth and survival of Her2-positive breast epithelial cells, making it a potential target for Her2-targeted therapies. In ovarian cancer, FAM177A1 (C14orf24) has been shown to promote the growth and survival of ovarian epithelial cells, making it a potential target for ovarian cancer therapies. In colorectal cancer, FAM177A1 (C14orf24) has been shown to promote the growth and survival of colon and rectal epithelial cells, making it a potential target for colorectal cancer therapies.

FAM177A1 (C14orf24) as a Biomarker

FAM177A1 (C14orf24) has also been shown to be a potential biomarker for cancer. Its levels have been shown to be reduced in various types of cancer, including breast, ovarian, and colorectal cancers. This suggests that FAM177A1 (C14orf24) may serve as a reliable biomarker for cancer diagnosis and monitoring.

FAM177A1 (C14orf24) has been shown to be expressed in various types of cancer, including breast, ovarian, and colorectal cancers. It has also been shown to be expressed in normal tissues, such as blood vessels and muscle cells. This suggests that FAM177A1 (C14orf24) may be a useful biomarker for detecting cancer at an early stage, as well as for monitoring cancer recurrence.

Conclusion

In conclusion, FAM177A1 (C14orf24) is a drug target and biomarker that has the potential to revolutionize cancer treatment. Its levels have been shown to be reduced in various types of cancer, making it an attractive target for small molecules, antibodies, or CRISPR/Cas9 genome editing techniques. Further studies are needed to fully understand the role of FAM177A1 (C14orf24) in cancer treatment and

Protein Name: Family With Sequence Similarity 177 Member A1

The "FAM177A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM177A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets